Compare · ARGX vs MAZE
ARGX vs MAZE
Side-by-side comparison of argenx SE (ARGX) and Maze Therapeutics Inc. (MAZE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and MAZE operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $53.51B, about 40.9x MAZE ($1.31B).
- Over the past year, ARGX is up 53.8% and MAZE is up 90.6% - MAZE leads by 36.8 points.
- MAZE has been more active in the news (16 items in the past 4 weeks vs 5 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 7 for MAZE).
- Company
- argenx SE
- Maze Therapeutics Inc.
- Price
- $886.37+2.86%
- $24.42+3.17%
- Market cap
- $53.51B
- $1.31B
- 1M return
- +8.74%
- -5.26%
- 1Y return
- +53.81%
- +90.58%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2025
- News (4w)
- 5
- 16
- Recent ratings
- 25
- 7
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest MAZE
- SEC Form 4 filed by Director Spiegelman Daniel K
- SEC Form 4 filed by Director Scheller Richard H
- SEC Form 4 filed by Director Lim Jonathan E
- SEC Form 4 filed by Director Hoppenot Herve
- SEC Form 4 filed by Director Homcy Charles J
- SEC Form 4 filed by Director Andrews Nancy C
- SEC Form 8-K filed by Maze Therapeutics Inc.
- Chief Executive Officer Coloma Jason V sold $174,048 worth of shares (6,643 units at $26.20) as part of a pre-agreed trading plan (SEC Form 4)
- President, R&D & CMO Bernstein Harold sold $381,112 worth of shares (14,853 units at $25.66) as part of a pre-agreed trading plan and exercised 14,853 shares at a strike of $10.42 (SEC Form 4)
- CSBO Dandekar Atul exercised 7,500 shares at a strike of $10.42 and sold $197,554 worth of shares (7,500 units at $26.34) as part of a pre-agreed trading plan (SEC Form 4)